AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE | A210876 | TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Shire Development LLC et al v. Teva Pharmaceuticals USA, Inc. et al 3 patentsANDA 210876Mixed salts of a single-entity amphetamine | D. Del. | 2017-11-22 | Terminated 2019-11-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$8.26
per ea
Lowest NADAC/Unit
$8.09
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00480368501DEXTROAMPH-AMPHET ER 37.5 MG CP | $8.26 | EA | Generic | — | 2026-06-17 |
| 00480368401DEXTROAMPH-AMPHET ER 25 MG CAP | $8.19 | EA | Generic | — | 2026-06-17 |
| 00480368601DEXTROAMPH-AMPHET ER 50 MG CAP | $8.18 | EA | Generic | — | 2026-06-17 |
| 00480368301DEXTROAMPH-AMPHET ER 12.5 MG CP | $8.09 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.